US5521184A
(en)
*
|
1992-04-03 |
1996-05-28 |
Ciba-Geigy Corporation |
Pyrimidine derivatives and processes for the preparation thereof
|
GB9212673D0
(en)
*
|
1992-06-15 |
1992-07-29 |
Celltech Ltd |
Chemical compounds
|
US6171786B1
(en)
|
1992-09-17 |
2001-01-09 |
Board Of Trustees Of University Of Illinois |
Methods for preventing multidrug resistance in cancer cells
|
US5972598A
(en)
*
|
1992-09-17 |
1999-10-26 |
Board Of Trustess Of The University Of Illinois |
Methods for preventing multidrug resistance in cancer cells
|
GB9222253D0
(en)
*
|
1992-10-23 |
1992-12-09 |
Celltech Ltd |
Chemical compounds
|
GB9304920D0
(en)
*
|
1993-03-10 |
1993-04-28 |
Celltech Ltd |
Chemical compounds
|
GB9304919D0
(en)
*
|
1993-03-10 |
1993-04-28 |
Celltech Ltd |
Chemical compounds
|
US5543520A
(en)
*
|
1993-10-01 |
1996-08-06 |
Ciba-Geigy Corporation |
Pyrimidine derivatives
|
CN1047776C
(en)
*
|
1993-10-01 |
1999-12-29 |
诺瓦蒂斯有限公司 |
Pharmacologically active pyridine derivatives and processes for the preparation thereof
|
PT672042E
(en)
*
|
1993-10-01 |
2006-08-31 |
Novartis Ag |
Pharmacologically active pyrimidineamine derivatives and processes for their preparation
|
US5612340A
(en)
*
|
1993-10-01 |
1997-03-18 |
Ciba-Geigy Corporation |
Pyrimidineamine derivatives and processes for the preparation thereof
|
GB9325217D0
(en)
*
|
1993-12-09 |
1994-02-09 |
Zeneca Ltd |
Pyrimidine derivatives
|
WO1995017399A1
(en)
*
|
1993-12-22 |
1995-06-29 |
Celltech Therapeutics Limited |
Trisubstituted phenyl derivatives, processes for their preparation and their use as phosphodiesterase (type iv) inhibitors
|
GB9326699D0
(en)
*
|
1993-12-22 |
1994-03-02 |
Celltech Ltd |
Chemical compounds
|
US5786354A
(en)
*
|
1994-06-21 |
1998-07-28 |
Celltech Therapeutics, Limited |
Tri-substituted phenyl derivatives and processes for their preparation
|
US6245774B1
(en)
|
1994-06-21 |
2001-06-12 |
Celltech Therapeutics Limited |
Tri-substituted phenyl or pyridine derivatives
|
GB9412571D0
(en)
*
|
1994-06-22 |
1994-08-10 |
Celltech Ltd |
Chemical compounds
|
GB9412573D0
(en)
|
1994-06-22 |
1994-08-10 |
Celltech Ltd |
Chemical compounds
|
GB9412672D0
(en)
*
|
1994-06-23 |
1994-08-10 |
Celltech Ltd |
Chemical compounds
|
US5756527A
(en)
*
|
1995-06-07 |
1998-05-26 |
Ontogen Corporation |
Imidazole derivatives useful as modulators of multi drug resistances
|
GB9523675D0
(en)
|
1995-11-20 |
1996-01-24 |
Celltech Therapeutics Ltd |
Chemical compounds
|
GB9526246D0
(en)
*
|
1995-12-21 |
1996-02-21 |
Celltech Therapeutics Ltd |
Chemical compounds
|
GB9526245D0
(en)
*
|
1995-12-21 |
1996-02-21 |
Celltech Therapeutics Ltd |
Chemical compounds
|
GB9608435D0
(en)
*
|
1996-04-24 |
1996-06-26 |
Celltech Therapeutics Ltd |
Chemical compounds
|
EP0812829A1
(en)
*
|
1996-06-14 |
1997-12-17 |
Ontogen Corporation |
Substituted imidazoles as modulators of multi-drug resistance
|
EP0812830A1
(en)
*
|
1996-06-14 |
1997-12-17 |
Ontogen Corporation |
Modulators of multi-drug resistances
|
GB9619284D0
(en)
*
|
1996-09-16 |
1996-10-30 |
Celltech Therapeutics Ltd |
Chemical compounds
|
GB9622363D0
(en)
|
1996-10-28 |
1997-01-08 |
Celltech Therapeutics Ltd |
Chemical compounds
|
GB9625184D0
(en)
*
|
1996-12-04 |
1997-01-22 |
Celltech Therapeutics Ltd |
Chemical compounds
|
AU5330698A
(en)
|
1996-12-23 |
1998-07-17 |
Celltech Therapeutics Limited |
Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
|
GB9705361D0
(en)
|
1997-03-14 |
1997-04-30 |
Celltech Therapeutics Ltd |
Chemical compounds
|
GB9713087D0
(en)
*
|
1997-06-20 |
1997-08-27 |
Celltech Therapeutics Ltd |
Chemical compounds
|
CO4940418A1
(en)
*
|
1997-07-18 |
2000-07-24 |
Novartis Ag |
MODIFICATION OF A CRYSTAL OF A DERIVATIVE OF N-PHENYL-2-PIRIMIDINAMINE, PROCESSES FOR ITS MANUFACTURE AND USE
|
GB9914258D0
(en)
|
1999-06-18 |
1999-08-18 |
Celltech Therapeutics Ltd |
Chemical compounds
|
AU5889100A
(en)
|
1999-06-30 |
2001-01-31 |
Merck & Co., Inc. |
Src kinase inhibitor compounds
|
DE60006541D1
(en)
|
1999-06-30 |
2003-12-18 |
Merck & Co Inc |
SRC-KINASE INHIBITING COMPOUNDS
|
EP1206260A4
(en)
|
1999-06-30 |
2002-10-30 |
Merck & Co Inc |
Src kinase inhibitor compounds
|
GB9919778D0
(en)
|
1999-08-21 |
1999-10-27 |
Zeneca Ltd |
Chemical compounds
|
CA2384101A1
(en)
|
1999-09-10 |
2001-03-15 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
GB9924862D0
(en)
|
1999-10-20 |
1999-12-22 |
Celltech Therapeutics Ltd |
Chemical compounds
|
WO2001060816A1
(en)
*
|
2000-02-17 |
2001-08-23 |
Amgen Inc. |
Kinase inhibitors
|
GB0004887D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
GB0004888D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
GB0004890D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
GB0004886D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
US7087608B2
(en)
*
|
2000-03-03 |
2006-08-08 |
Robert Charles Atkins |
Use of PDGF receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy
|
GB0007371D0
(en)
|
2000-03-28 |
2000-05-17 |
Astrazeneca Uk Ltd |
Chemical compounds
|
US7030219B2
(en)
|
2000-04-28 |
2006-04-18 |
Johns Hopkins University |
B7-DC, Dendritic cell co-stimulatory molecules
|
EP1964839A3
(en)
|
2000-08-18 |
2008-11-05 |
Millennium Pharmaceuticals, Inc. |
Quinazoline derivatives as kinase inhibitors
|
GB0022438D0
(en)
|
2000-09-13 |
2000-11-01 |
Novartis Ag |
Organic Compounds
|
PT1332137E
(en)
*
|
2000-10-27 |
2006-07-31 |
Novartis Ag |
TREATMENT OF GASTRINTESTINAL STROMAL TUMORS
|
JP4564713B2
(en)
|
2000-11-01 |
2010-10-20 |
ミレニアム・ファーマシューティカルズ・インコーポレイテッド |
Nitrogen heterocyclic compounds, and methods for making nitrogen heterocyclic compounds and intermediates thereof
|
GB0103926D0
(en)
*
|
2001-02-17 |
2001-04-04 |
Astrazeneca Ab |
Chemical compounds
|
LT3351246T
(en)
|
2001-02-19 |
2019-07-10 |
Novartis Pharma Ag |
Rapamycin derivative for the treatment of a solid tumor associated with deregulated angiogenesis
|
SE0100569D0
(en)
*
|
2001-02-20 |
2001-02-20 |
Astrazeneca Ab |
New compounds
|
BR0207649A
(en)
*
|
2001-02-27 |
2004-03-09 |
Novartis Ag |
A combination comprising a signal transduction inhibitor and an epothilone derivative
|
KR20080091866A
(en)
|
2001-05-16 |
2008-10-14 |
노파르티스 아게 |
Combination comprising n-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and a chemotherapeutic agent
|
EP1395261B1
(en)
*
|
2001-05-16 |
2006-06-28 |
GPC Biotech AG |
Pyridylpyrimidine derivatives as effective compounds against prion diseases
|
EP1466174B1
(en)
|
2001-06-14 |
2009-05-13 |
The Regents of the University of California |
Mutations in the bcr-abl tyrosine kinase associated with resistance to sti-571
|
AU2002315388A1
(en)
|
2001-06-21 |
2003-01-08 |
Ariad Pharmaceuticals, Inc. |
Novel phenylamino-pyrimidines and uses thereof
|
CA2450562A1
(en)
|
2001-06-22 |
2003-01-03 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
US7727731B2
(en)
|
2001-06-29 |
2010-06-01 |
Ab Science |
Potent, selective and non toxic c-kit inhibitors
|
EP1401413B1
(en)
|
2001-06-29 |
2006-11-22 |
AB Science |
Use of tyrosine kinase inhibitions for treating allergic diseases
|
ATE343415T1
(en)
|
2001-06-29 |
2006-11-15 |
Ab Science |
THE USE OF C-KIT INHIBITORS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE
|
EP1401412A2
(en)
*
|
2001-06-29 |
2004-03-31 |
AB Science |
Use of potent, selective and non toxic c-kit inhibitors for treating tumor angiogenesis
|
DE60212627T2
(en)
|
2001-06-29 |
2007-06-14 |
Ab Science |
Use of tyrosine kinase inhibitors for the treatment of inflammatory diseases
|
US20060204459A1
(en)
*
|
2001-09-20 |
2006-09-14 |
Alain Moussy |
Use of tyrosine inhibitors for whitening human skin and treating melanocyted dysfunction associated diseases
|
WO2003040141A1
(en)
*
|
2001-09-28 |
2003-05-15 |
Bayer Pharmaceuticals Corporation |
Oxazolyl-phenyl-2,4-diamino-pyrimidine compounds and methods for treating hyperproliferative disorders
|
US20050202519A1
(en)
|
2001-10-05 |
2005-09-15 |
Christophe Barthe |
Mutated abl kinase domains
|
GB0201508D0
(en)
*
|
2002-01-23 |
2002-03-13 |
Novartis Ag |
Organic compounds
|
AU2007203463B2
(en)
*
|
2002-02-07 |
2010-12-23 |
Novartis Pharma Ag |
N-phenyl-2-pyrimidine-amine derivatives
|
GB0202873D0
(en)
|
2002-02-07 |
2002-03-27 |
Novartis Ag |
Organic compounds
|
GB0202874D0
(en)
*
|
2002-02-07 |
2002-03-27 |
Novartis Ag |
Organic compounds
|
ATE326970T1
(en)
*
|
2002-02-22 |
2006-06-15 |
Us Gov Veterans Affairs |
USE OF 4-(4-METHYLPIPERAZINE-1-YLMETHYL)-N 4-METHYL-3-(4-PYRIDINE-3-YL) PYRIMIDINE-2-YLAMINO) PHENYL BENZAMIDE FOR THE TREATMENT OF SEMINOMAS
|
CA2477726A1
(en)
*
|
2002-02-27 |
2003-09-04 |
Ab Science |
Use of tyrosine kinase inhibitors for treating substance use disorders
|
US20050222091A1
(en)
*
|
2002-02-27 |
2005-10-06 |
Alain Moussy |
Use of tyrosine kinase inhibitors for treating cns disorders
|
KR20040093058A
(en)
*
|
2002-02-28 |
2004-11-04 |
노파르티스 아게 |
N-(5-(4-(4-methyl-piperazino-methyl)-benzoylamido)-2-methylphenyl)-4-(3-pyridyl)-2-pyrimidine-amine coated stents
|
GB0206215D0
(en)
|
2002-03-15 |
2002-05-01 |
Novartis Ag |
Organic compounds
|
GB0209265D0
(en)
*
|
2002-04-23 |
2002-06-05 |
Novartis Ag |
Organic compounds
|
WO2003095448A1
(en)
*
|
2002-05-06 |
2003-11-20 |
Bayer Pharmaceuticals Corporation |
Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders
|
ES2316758T3
(en)
|
2002-05-16 |
2009-04-16 |
Novartis Ag |
USE OF EDG RECEIVER BINDERS IN CANCER.
|
AU2003249369A1
(en)
|
2002-06-21 |
2004-01-06 |
Cellular Genomics, Inc. |
Certain amino-substituted monocycles as kinase modulators
|
US20060052387A1
(en)
*
|
2002-06-26 |
2006-03-09 |
Marsh Clay B |
Organic compounds
|
JP4552650B2
(en)
*
|
2002-06-28 |
2010-09-29 |
日本新薬株式会社 |
Amide derivatives and pharmaceuticals
|
GB0215676D0
(en)
*
|
2002-07-05 |
2002-08-14 |
Novartis Ag |
Organic compounds
|
US6872724B2
(en)
|
2002-07-24 |
2005-03-29 |
Merck & Co., Inc. |
Polymorphs with tyrosine kinase activity
|
DK1525200T3
(en)
*
|
2002-08-02 |
2007-12-03 |
Ab Science |
2- (3-aminoaryl) amino-4-aryl-thiazoles for disease treatment
|
GB0222514D0
(en)
*
|
2002-09-27 |
2002-11-06 |
Novartis Ag |
Organic compounds
|
US7879868B2
(en)
*
|
2002-10-11 |
2011-02-01 |
Novartis Ag |
Use of imatinib (glivec,sti-571) to inhibit breast cancer resistance protein (BCRP)-mediated resistance to therapeutic agents
|
GB0224455D0
(en)
*
|
2002-10-21 |
2002-11-27 |
Novartis Ag |
Organic compounds
|
US7094785B1
(en)
|
2002-12-18 |
2006-08-22 |
Cornell Research Foundation, Inc. |
Method of treating polycythemia vera
|
US7144911B2
(en)
*
|
2002-12-31 |
2006-12-05 |
Deciphera Pharmaceuticals Llc |
Anti-inflammatory medicaments
|
GB2398565A
(en)
|
2003-02-18 |
2004-08-25 |
Cipla Ltd |
Imatinib preparation and salts
|
ZA200507803B
(en)
*
|
2003-04-04 |
2007-03-28 |
Bayco Tech Ltd |
Vascular stent
|
WO2004099186A1
(en)
|
2003-05-06 |
2004-11-18 |
Il Yang Pharm Co., Ltd. |
N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof
|
ES2467160T3
(en)
|
2003-05-19 |
2014-06-12 |
Irm Llc |
Immunosuppressive compounds and compositions
|
MY150088A
(en)
|
2003-05-19 |
2013-11-29 |
Irm Llc |
Immunosuppressant compounds and compositions
|
DK1631291T3
(en)
*
|
2003-05-27 |
2009-11-02 |
Robert P Haegerkvist |
Use of tyrosine kinase inhibitors to treat diabetes
|
JP2006527230A
(en)
*
|
2003-06-13 |
2006-11-30 |
ノバルティス アクチエンゲゼルシャフト |
2-Aminopyrimidine derivatives as RAF kinase inhibitors
|
NZ601544A
(en)
|
2003-08-27 |
2013-11-29 |
Ophthotech Corp |
Combination therapy for the treatment of ocular neovascular disorders
|
RU2362562C2
(en)
|
2003-11-18 |
2009-07-27 |
Новартис Аг |
Inhibitors of mutant form of kinase kit
|
WO2005063709A1
(en)
*
|
2003-12-25 |
2005-07-14 |
Nippon Shinyaku Co., Ltd. |
Amide derivative and medicine
|
EP1725295B1
(en)
*
|
2004-01-21 |
2010-09-15 |
Emory University |
Compositions and use of tyrosine kinase inhibitors to treat pathogenic infection
|
AR047530A1
(en)
|
2004-02-04 |
2006-01-25 |
Novartis Ag |
FORMS OF SALT OF 4- (4-METHYLIPIPERAZIN-1-ILMETIL) -N- (4-METHYL-3- (4-PIRIDIN-3-IL) PIRIMIDIN-2-ILAMINO) PHENYL) -BENZAMIDA
|
WO2005077933A1
(en)
*
|
2004-02-11 |
2005-08-25 |
Natco Pharma Limited |
Novel polymorphic form of imatinib mesylate and a process for its preparation
|
CN1309719C
(en)
*
|
2004-02-18 |
2007-04-11 |
陈国庆 |
Derivative of phenylamide pyrimidine and application thereof
|
DK2253614T3
(en)
|
2004-04-07 |
2013-01-07 |
Novartis Ag |
IAP inhibitors
|
GB0512324D0
(en)
|
2005-06-16 |
2005-07-27 |
Novartis Ag |
Organic compounds
|
CA2578122A1
(en)
*
|
2004-08-27 |
2006-03-02 |
Gpc Biotech Ag |
Pyrimidine derivatives
|
WO2006024863A1
(en)
|
2004-09-02 |
2006-03-09 |
Cipla Limited |
Stable crystal form of imatinib mesylate and process for the preparation thereof
|
US8735415B2
(en)
|
2004-09-09 |
2014-05-27 |
Natco Pharma Limited |
Acid addition salts of (3,5-Bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide
|
US7939541B2
(en)
|
2004-09-09 |
2011-05-10 |
Natco Pharma Limited |
Intermediates and a process employing the intermediates for the preparation of (3-trifluoromethylsulfonyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide
|
EA013328B1
(en)
|
2004-09-09 |
2010-04-30 |
Натко Фарма Лимитед |
Novel phenylaminopyrimidine derivatives as inhibitors of bcr-abl kinase
|
WO2006054314A1
(en)
*
|
2004-11-17 |
2006-05-26 |
Natco Pharma Limited |
Polymorphic forms of imatinib mesylate
|
SI1833815T1
(en)
*
|
2004-12-30 |
2011-01-31 |
Inst Farmaceutyczny |
A process for preparation of imatinib base
|
CN1939910A
(en)
*
|
2004-12-31 |
2007-04-04 |
孙飘扬 |
Amino-metadiazine compound and its salt, its preparation and pharmaceutical use
|
CN1972917B
(en)
*
|
2004-12-31 |
2010-08-25 |
孙飘扬 |
Aminopyrimidine compounds and their salts, process for preparation and pharmaceutical use thereof
|
JP5475234B2
(en)
|
2005-01-21 |
2014-04-16 |
アステックス・セラピューティクス・リミテッド |
Pharmaceutical compounds
|
EP1879585B1
(en)
|
2005-05-02 |
2013-04-17 |
Novartis AG |
Use of pyrimidylamimobenzamide derivatives for the treatment of systemic mastocytosis
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
UA96139C2
(en)
|
2005-11-08 |
2011-10-10 |
Дженентек, Інк. |
Anti-neuropilin-1 (nrp1) antibody
|
JP2009516671A
(en)
|
2005-11-21 |
2009-04-23 |
ノバルティス アクチエンゲゼルシャフト |
Neuroendocrine tumor treatment using mTOR inhibitors
|
MY146403A
(en)
|
2005-11-25 |
2012-08-15 |
Novartis Ag |
F, g, h, i and k crystal forms of imatinib mesylate
|
GB0605120D0
(en)
|
2006-03-14 |
2006-04-26 |
Novartis Ag |
Organic Compounds
|
MX2008012715A
(en)
|
2006-04-05 |
2008-10-14 |
Novartis Ag |
Combinations of therapeutic agents for treating cancer.
|
EP2606890A1
(en)
|
2006-04-05 |
2013-06-26 |
Novartis AG |
Combinations comprising BCR-ABL/C-KIT/PDGF-R TK inhibitors for treating cancer
|
PE20080251A1
(en)
|
2006-05-04 |
2008-04-25 |
Boehringer Ingelheim Int |
USES OF DPP IV INHIBITORS
|
NZ572299A
(en)
|
2006-05-09 |
2010-07-30 |
Novartis Ag |
Combination comprising a substituted 3,5-diphenyl-1,2,4-triazole and a platinum compound and use thereof
|
US20060223817A1
(en)
*
|
2006-05-15 |
2006-10-05 |
Chemagis Ltd. |
Crystalline imatinib base and production process therefor
|
WO2007138705A1
(en)
|
2006-06-01 |
2007-12-06 |
Japan As Represented By Director General Of Agency Of National Cancer Center |
Tumor suppressor
|
RU2009115954A
(en)
|
2006-09-29 |
2010-11-10 |
Новартис АГ (CH) |
Pyrazolopyrimidines as P13K Lipid Kinase Inhibitors
|
JP5528806B2
(en)
|
2006-10-12 |
2014-06-25 |
アステックス、セラピューティックス、リミテッド |
Compound drug
|
JP5528807B2
(en)
|
2006-10-12 |
2014-06-25 |
アステックス、セラピューティックス、リミテッド |
Compound drug
|
JP2009514988A
(en)
*
|
2006-10-26 |
2009-04-09 |
シコール インコーポレイティド |
Imatinib base and imatinib mesylate and methods for their preparation
|
US8168787B2
(en)
|
2006-11-16 |
2012-05-01 |
F.I.S. Fabbrica Italiana Sintetici S.P.A. |
Process for the preparation of imatinib and intermediates thereof
|
CN101245061B
(en)
*
|
2007-02-13 |
2012-09-19 |
天津天士力集团有限公司 |
N-(5-amido-2-methyl phenyl)-4-(3-pyridinyl)-2-aminopyrimidine nitric oxide donating derivant, production method and uses thereof
|
WO2008100985A2
(en)
|
2007-02-15 |
2008-08-21 |
Novartis Ag |
Combination of lbh589 with other therapeutic agents for treating cancer
|
RU2329260C1
(en)
*
|
2007-02-20 |
2008-07-20 |
Юрий Иосифович Копырин |
Method of obtaining 2-anilinopyrimidines or their salts (options)
|
WO2008112722A2
(en)
*
|
2007-03-12 |
2008-09-18 |
Dr. Reddy's Laboratories Ltd. |
Imatinib mesylate
|
WO2008117298A1
(en)
*
|
2007-03-26 |
2008-10-02 |
Natco Pharma Limited |
A novel method of preparation of imatinib
|
US7550591B2
(en)
|
2007-05-02 |
2009-06-23 |
Chemagis Ltd. |
Imatinib production process
|
WO2008136010A1
(en)
*
|
2007-05-07 |
2008-11-13 |
Natco Pharma Limited |
A process for the preparation of highly pure imatinib base
|
WO2008153974A1
(en)
|
2007-06-07 |
2008-12-18 |
Intra-Cellular Therapies, Inc. |
Novel heterocycle compounds and uses thereof
|
JP5710251B2
(en)
|
2007-06-07 |
2015-04-30 |
イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. |
Novel heterocyclic compounds and uses thereof
|
CA2698511C
(en)
*
|
2007-09-04 |
2016-10-11 |
The Scripps Research Institute |
Substituted pyrimidinyl-amines as protein kinase inhibitors
|
WO2009060463A1
(en)
*
|
2007-11-05 |
2009-05-14 |
Natco Pharma Limited |
An environmentally friendly process for the preparation of imatinib base
|
EP2062885A1
(en)
*
|
2007-11-21 |
2009-05-27 |
Eczacibasi-Zentiva Kimyasal Ürünler Sanayi ve Ticaret A.S. |
Acid addition salts of imatinib and formulations comprising the same
|
WO2009095399A2
(en)
*
|
2008-02-01 |
2009-08-06 |
Akinion Pharmaceuticals Ab |
Pyrazine derivatives and their use as protein kinase inhbitors
|
MX2010010525A
(en)
|
2008-03-24 |
2010-10-25 |
Novartis Ag |
Arylsulfonamide-based matrix metalloprotease inhibitors.
|
GEP20125708B
(en)
|
2008-03-26 |
2012-12-10 |
Novartis Ag |
Hydroxamate-based inhibitors of deacetylases b
|
US9273077B2
(en)
|
2008-05-21 |
2016-03-01 |
Ariad Pharmaceuticals, Inc. |
Phosphorus derivatives as kinase inhibitors
|
NO2300013T3
(en)
|
2008-05-21 |
2018-02-03 |
|
|
CN101584696A
(en)
|
2008-05-21 |
2009-11-25 |
上海艾力斯医药科技有限公司 |
Composition containing quinazoline derivatives, preparation method and use
|
PL215042B1
(en)
*
|
2008-08-01 |
2013-10-31 |
Temapharm Spolka Z Ograniczona Odpowiedzialnoscia |
Method of imatinib manufacturing
|
UY32030A
(en)
|
2008-08-06 |
2010-03-26 |
Boehringer Ingelheim Int |
"TREATMENT FOR DIABETES IN INAPPROPRIATE PATIENTS FOR THERAPY WITH METFORMIN"
|
MX2011001525A
(en)
|
2008-08-15 |
2011-03-29 |
Boehringer Ingelheim Int |
Purin derivatives for use in the treatment of fab-related diseases.
|
EA023148B1
(en)
|
2008-08-25 |
2016-04-29 |
Эмплиммьюн, Инк. |
Compositions of pd-1 antagonists and use thereof
|
ES2704986T3
(en)
|
2008-10-16 |
2019-03-21 |
Celator Pharmaceuticals Inc |
Combinations of a water-soluble liposomal camptothecin with cetuximab or bevacizumab
|
EP2186514B1
(en)
|
2008-11-14 |
2016-06-29 |
Kinki University |
Treatment of Malignant Peripheral Nerve Sheath Tumors
|
EP2379499B1
(en)
|
2008-12-18 |
2014-04-09 |
Novartis AG |
Hydrochloride salt of 1-(4-(1-((E)-4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl)-2-ethyl-benzyl)-azetidine-3-carboxylic acid
|
BRPI0922457A2
(en)
|
2008-12-18 |
2015-12-15 |
Novartis Ag |
polymorphic form of 1- (4- {1 - [(e) -4-cyclohexyl-3-trifluoromethyl-benzyloxy-imino] -ethyl) -2-ethyl-benzyl) -azetidine-3-carboxylic acid "
|
KR20160129915A
(en)
|
2008-12-18 |
2016-11-09 |
노파르티스 아게 |
Hemifumarate salt of 1-[4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl]-azetidine-3-carboxylic acid
|
BRPI0923121A2
(en)
|
2008-12-23 |
2015-08-11 |
Boehringer Ingelheim Int |
Saline forms of organic compounds
|
TW201036975A
(en)
|
2009-01-07 |
2010-10-16 |
Boehringer Ingelheim Int |
Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
|
WO2010083617A1
(en)
|
2009-01-21 |
2010-07-29 |
Oncalis Ag |
Pyrazolopyrimidines as protein kinase inhibitors
|
DK2391366T3
(en)
|
2009-01-29 |
2013-01-07 |
Novartis Ag |
Substituted benzimidazoles for the treatment of astrocytomas
|
TWI466672B
(en)
|
2009-01-29 |
2015-01-01 |
Boehringer Ingelheim Int |
Treatment for diabetes in paediatric patients
|
EA029759B1
(en)
|
2009-02-13 |
2018-05-31 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Antidiabetic medications comprising dpp-4 inhibitor (linagliptin) optionally in combination with other antidiabetic agents
|
JP2012518657A
(en)
|
2009-02-25 |
2012-08-16 |
オーエスアイ・ファーマシューティカルズ,エルエルシー |
Combined anticancer treatment
|
JP2012519282A
(en)
|
2009-02-27 |
2012-08-23 |
オーエスアイ・ファーマシューティカルズ,エルエルシー |
Methods for identifying mesenchymal tumor cells or agents that inhibit their production
|
JP2012519281A
(en)
|
2009-02-27 |
2012-08-23 |
オーエスアイ・ファーマシューティカルズ,エルエルシー |
Methods for identifying mesenchymal tumor cells or agents that inhibit their production
|
WO2010099138A2
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
UA103918C2
(en)
|
2009-03-02 |
2013-12-10 |
Айерем Элелси |
N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
|
TW201102068A
(en)
|
2009-06-02 |
2011-01-16 |
Novartis Ag |
Treatment of ophthalmologic disorders mediated by alpha-carbonic anhydrase isoforms
|
JP5456891B2
(en)
|
2009-06-26 |
2014-04-02 |
ノバルティス アーゲー |
1,3-disubstituted imidazolidin-2-one derivatives as CYP17 inhibitors
|
WO2011014520A2
(en)
|
2009-07-29 |
2011-02-03 |
Irm Llc |
Compounds and compositions as modulators of gpr119 activity
|
US8389526B2
(en)
|
2009-08-07 |
2013-03-05 |
Novartis Ag |
3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
|
MX2012001838A
(en)
|
2009-08-12 |
2012-02-29 |
Novartis Ag |
Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation.
|
AU2010284254B2
(en)
|
2009-08-17 |
2015-09-17 |
Intellikine, Llc |
Heterocyclic compounds and uses thereof
|
AU2010284972A1
(en)
|
2009-08-20 |
2012-03-08 |
Novartis Ag |
Heterocyclic oxime compounds
|
AU2010288534A1
(en)
|
2009-08-26 |
2012-03-15 |
Novartis Ag |
Tetra-substituted heteroaryl compounds and their use as MDM2 and/or MDM4 modulators
|
US20120165310A1
(en)
|
2009-09-10 |
2012-06-28 |
Novartis Ag |
Ether derivatives of bicyclic heteroaryls
|
NZ598170A
(en)
|
2009-10-02 |
2014-06-27 |
Boehringer Ingelheim Int |
Pharmaceutical compositions comprising bi-1356 and metformin
|
US8575168B2
(en)
|
2009-10-09 |
2013-11-05 |
Irm Llc |
Compounds and compositions as modulators of GPR119 activity
|
PL389357A1
(en)
|
2009-10-22 |
2011-04-26 |
Tomasz Koźluk |
Tartaric acids derivatives imatinib salts and process for the preparation thereof
|
CA2779935A1
(en)
|
2009-11-04 |
2011-05-12 |
Novartis Ag |
Heterocyclic sulfonamide derivatives useful as mek inhibitors
|
EA201200617A1
(en)
|
2009-11-23 |
2012-11-30 |
Серулин Фарма Инк. |
POLYMERS ON THE BASIS OF CYCLODEXTRINE FOR DELIVERY OF MEDICINES
|
CN102712648A
(en)
|
2009-11-25 |
2012-10-03 |
诺瓦提斯公司 |
Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls
|
ES2760917T3
(en)
|
2009-11-27 |
2020-05-18 |
Boehringer Ingelheim Int |
Treatment of diabetic patients genotyped with DPP-IV inhibitors such as linagliptin
|
US8394858B2
(en)
|
2009-12-03 |
2013-03-12 |
Novartis Ag |
Cyclohexane derivatives and uses thereof
|
GEP20135998B
(en)
|
2009-12-08 |
2013-12-25 |
Novartis Ag |
Heterocyclic sulfonamide derivatives
|
US20110306763A1
(en)
|
2009-12-10 |
2011-12-15 |
Shanghai Parling Pharmatech Co., Ltd. |
Process for the preparation of imatinib and salts thereof
|
CU24130B1
(en)
|
2009-12-22 |
2015-09-29 |
Novartis Ag |
ISOQUINOLINONES AND REPLACED QUINAZOLINONES
|
US8440693B2
(en)
|
2009-12-22 |
2013-05-14 |
Novartis Ag |
Substituted isoquinolinones and quinazolinones
|
US20110178287A1
(en)
|
2010-01-19 |
2011-07-21 |
Cerulean Pharma Inc. |
Cyclodextrin-based polymers for therapeutic delivery
|
JP2013519665A
(en)
|
2010-02-15 |
2013-05-30 |
リライアンス ライフ サイエンシズ ピーヴィーティー リミティッド |
Process for producing α form of imatinib mesylate
|
PL390611A1
(en)
|
2010-03-04 |
2011-09-12 |
Tomasz Koźluk |
Process for the preparation of polymorphic alpha form and new polymorphic form of imatinib mesylate
|
KR20130055576A
(en)
|
2010-03-15 |
2013-05-28 |
낫코 파마 리미티드 |
Process for the preparation of highly pure crystalline imatinib base
|
WO2011113947A1
(en)
|
2010-03-18 |
2011-09-22 |
Boehringer Ingelheim International Gmbh |
Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions
|
US20110237686A1
(en)
|
2010-03-26 |
2011-09-29 |
Cerulean Pharma Inc |
Formulations and methods of use
|
WO2011130918A1
(en)
*
|
2010-04-23 |
2011-10-27 |
上海百灵医药科技有限公司 |
Process for synthesizing imatinib
|
EP2382976A1
(en)
|
2010-04-30 |
2011-11-02 |
Hiroshima University |
Use of pdgf-r inhibitors for the treatment of lymph node metastasis of gastric cancer
|
JP6034781B2
(en)
|
2010-05-05 |
2016-11-30 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Combination therapy
|
JP2013532149A
(en)
|
2010-06-17 |
2013-08-15 |
ノバルティス アーゲー |
Piperidinyl-substituted 1,3-dihydro-benzimidazol-2-ylideneamine derivatives
|
WO2011157787A1
(en)
|
2010-06-17 |
2011-12-22 |
Novartis Ag |
Biphenyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
|
SI2582689T1
(en)
|
2010-06-18 |
2017-05-31 |
Krka, D.D., Novo Mesto |
New polymorphic form of imatinib base and preparation of salts thereof
|
WO2011160798A1
(en)
|
2010-06-21 |
2011-12-29 |
Zaklady Farmaceutyczne Polpharma Sa |
Pharmaceutical compositions comprising imatinib or pharmaceutically acceptable salt thereof and processes for the manufacture thereof
|
CA3164653A1
(en)
|
2010-06-24 |
2011-12-29 |
Boehringer Ingelheim International Gmbh |
A combination comprising linagliptin and a long-acting insulin
|
UA112517C2
(en)
|
2010-07-06 |
2016-09-26 |
Новартіс Аг |
TETRAHYDROPYRIDOPYRIMIDINE DERIVATIVES
|
EP2591004A1
(en)
|
2010-07-09 |
2013-05-15 |
F.Hoffmann-La Roche Ag |
Anti-neuropilin antibodies and methods of use
|
US8697739B2
(en)
|
2010-07-29 |
2014-04-15 |
Novartis Ag |
Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof
|
WO2012019633A1
(en)
|
2010-08-11 |
2012-02-16 |
Synthon B.V. |
Pharmaceutical granulate comprising imatinib mesylate
|
TR201007005A2
(en)
|
2010-08-23 |
2011-09-21 |
Mustafa Nevzat İlaç Sanayi̇i̇ A.Ş. |
Imatinib base production method
|
WO2012035078A1
(en)
|
2010-09-16 |
2012-03-22 |
Novartis Ag |
17α-HYDROXYLASE/C17,20-LYASE INHIBITORS
|
US9034883B2
(en)
|
2010-11-15 |
2015-05-19 |
Boehringer Ingelheim International Gmbh |
Vasoprotective and cardioprotective antidiabetic therapy
|
TR201010618A2
(en)
|
2010-12-20 |
2012-07-23 |
Bi̇lgi̇ç Mahmut |
An oral dosage form comprising imatinib and the manufacture of an oral dosage form
|
BR112013015449A2
(en)
|
2010-12-21 |
2016-09-20 |
Novartis Ag |
biheteroaryl compounds as vps23 inhibitors
|
WO2012090221A1
(en)
|
2010-12-29 |
2012-07-05 |
Cadila Healthcare Limited |
Novel salts of imatinib
|
WO2012107500A1
(en)
|
2011-02-10 |
2012-08-16 |
Novartis Ag |
[1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
|
TWI592411B
(en)
|
2011-02-23 |
2017-07-21 |
英特爾立秦有限責任公司 |
Combination of kinase inhibitors and uses thereof
|
US9127000B2
(en)
|
2011-02-23 |
2015-09-08 |
Intellikine, LLC. |
Heterocyclic compounds and uses thereof
|
CZ305457B6
(en)
|
2011-02-28 |
2015-09-30 |
Ústav organické chemie a biochemie, Akademie věd ČR v. v. i. |
Pyrimidine compounds inhibiting formation of nitrogen monoxide and prostaglandin E2, process for their preparation and use
|
EP2683722A1
(en)
|
2011-03-08 |
2014-01-15 |
Novartis AG |
Fluorophenyl bicyclic heteroaryl compounds
|
PL394169A1
(en)
|
2011-03-09 |
2012-09-10 |
Adamed Spółka Z Ograniczoną Odpowiedzialnością |
The pharmaceutical composition of imatinib mesylate for filling unit dosage forms and the method for its preparation
|
EP2508525A1
(en)
|
2011-04-05 |
2012-10-10 |
Bayer Pharma Aktiengesellschaft |
Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
|
EP2702173A1
(en)
|
2011-04-25 |
2014-03-05 |
OSI Pharmaceuticals, LLC |
Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
|
EP2702052B1
(en)
|
2011-04-28 |
2017-10-18 |
Novartis AG |
17alpha-hydroxylase/c17,20-lyase inhibitors
|
WO2012151561A1
(en)
|
2011-05-04 |
2012-11-08 |
Ariad Pharmaceuticals, Inc. |
Compounds for inhibiting cell proliferation in egfr-driven cancers
|
CN102796110B
(en)
*
|
2011-05-23 |
2016-03-30 |
复旦大学 |
Aniline pyrimidine compound and its production and use
|
EA201391820A1
(en)
|
2011-06-09 |
2014-12-30 |
Новартис Аг |
HETEROCYCLIC SULPHONAMIDE DERIVATIVES
|
US8859535B2
(en)
|
2011-06-20 |
2014-10-14 |
Novartis Ag |
Hydroxy substituted isoquinolinone derivatives
|
US8859586B2
(en)
|
2011-06-20 |
2014-10-14 |
Novartis Ag |
Cyclohexyl isoquinolinone compounds
|
US9750700B2
(en)
|
2011-06-22 |
2017-09-05 |
Natco Pharma Limited |
Imatinib mesylate oral pharmaceutical composition and process for preparation thereof
|
MX2013015001A
(en)
|
2011-06-27 |
2014-03-31 |
Novartis Ag |
Solid forms and salts of tetrahydro-pyrido-pyrimidine derivatives.
|
ITMI20111309A1
(en)
|
2011-07-14 |
2013-01-15 |
Italiana Sint Spa |
PREPARATION PROCEDURE OF IMATINIB MESILATO
|
US8883800B2
(en)
|
2011-07-15 |
2014-11-11 |
Boehringer Ingelheim International Gmbh |
Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
|
WO2013035102A1
(en)
|
2011-09-05 |
2013-03-14 |
Natco Pharma Limited |
Processes for the preparation of imatinib base and intermediates thereof
|
JP5957526B2
(en)
|
2011-09-15 |
2016-07-27 |
ノバルティス アーゲー |
6-Substituted 3- (quinolin-6-ylthio)-[1,2,4] triazolo [4,3-A] pyrazine as tyrosine kinase
|
MX352749B
(en)
|
2011-11-01 |
2017-12-06 |
Modgene Llc |
Compositions and methods for reduction of amyloid-beta load.
|
RU2486180C1
(en)
*
|
2011-11-02 |
2013-06-27 |
Общество с ограниченной ответственностью "ТехноХим" (ООО "ТехноХим") |
Method for preparing 2-arylamino-4-hetarylpyrimidines
|
EP2785717B1
(en)
|
2011-11-29 |
2016-01-13 |
Novartis AG |
Pyrazolopyrrolidine compounds
|
US9408885B2
(en)
|
2011-12-01 |
2016-08-09 |
Vib Vzw |
Combinations of therapeutic agents for treating melanoma
|
CN103159739A
(en)
*
|
2011-12-09 |
2013-06-19 |
天津市国际生物医药联合研究院有限公司 |
1, 4-disubstituted-1, 2, 3-triazole compounds and preparation method thereof
|
US20150148377A1
(en)
|
2011-12-22 |
2015-05-28 |
Novartis Ag |
Quinoline Derivatives
|
AP4055A
(en)
|
2011-12-22 |
2017-03-07 |
Novartis Ag |
Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives
|
CA2859862A1
(en)
|
2011-12-23 |
2013-06-27 |
Novartis Ag |
Compounds for inhibiting the interaction of bcl2 with binding partners
|
MX2014007732A
(en)
|
2011-12-23 |
2015-01-12 |
Novartis Ag |
Compounds for inhibiting the interaction of bcl2 with binding partners.
|
AU2012355615A1
(en)
|
2011-12-23 |
2014-07-10 |
Novartis Ag |
Compounds for inhibiting the interaction of BCL2 with binding partners
|
KR20140107574A
(en)
|
2011-12-23 |
2014-09-04 |
노파르티스 아게 |
Compounds for inhibiting the interaction of bcl2 with binding partners
|
US20130178520A1
(en)
|
2011-12-23 |
2013-07-11 |
Duke University |
Methods of treatment using arylcyclopropylamine compounds
|
EP2794591A1
(en)
|
2011-12-23 |
2014-10-29 |
Novartis AG |
Compounds for inhibiting the interaction of bcl2 with binding partners
|
US20130172244A1
(en)
|
2011-12-29 |
2013-07-04 |
Thomas Klein |
Subcutaneous therapeutic use of dpp-4 inhibitor
|
PL226174B1
(en)
|
2011-12-30 |
2017-06-30 |
Inst Farm |
Combination therapy of non-small-cell lung carcinoma
|
US8815926B2
(en)
|
2012-01-26 |
2014-08-26 |
Novartis Ag |
Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases
|
WO2013120852A1
(en)
|
2012-02-13 |
2013-08-22 |
Grindeks, A Joint Stock Company |
Intermediates for a novel process of preparing imatinib and related tyrosine kinase inhibitors
|
WO2013136141A1
(en)
|
2012-03-13 |
2013-09-19 |
Fresenius Kabi Oncology Ltd. |
An improved process for the preparation of alpha form of imatinib mesylate
|
CN104245701A
(en)
|
2012-04-03 |
2014-12-24 |
诺华有限公司 |
Combination products with tyrosine kinase inhibitors and their use
|
WO2013152252A1
(en)
|
2012-04-06 |
2013-10-10 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
WO2013161851A1
(en)
|
2012-04-24 |
2013-10-31 |
中外製薬株式会社 |
Benzamide derivative
|
CN104379568A
(en)
|
2012-04-24 |
2015-02-25 |
中外制药株式会社 |
Quinazolinedione derivative
|
WO2013169401A1
(en)
|
2012-05-05 |
2013-11-14 |
Ariad Pharmaceuticals, Inc. |
Compounds for inhibiting cell proliferation in egfr-driven cancers
|
WO2013171166A1
(en)
|
2012-05-14 |
2013-11-21 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp-4 inhibitor for use in the treatment of sirs and/or sepsis
|
EP2849755A1
(en)
|
2012-05-14 |
2015-03-25 |
Boehringer Ingelheim International GmbH |
A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
|
EP2854812A1
(en)
|
2012-05-24 |
2015-04-08 |
Boehringer Ingelheim International GmbH |
A xanthine derivative as dpp -4 inhibitor for use in the treatment of autoimmune diabetes, particularly lada
|
WO2013174767A1
(en)
|
2012-05-24 |
2013-11-28 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
|
JP6171003B2
(en)
|
2012-05-24 |
2017-07-26 |
ノバルティス アーゲー |
Pyrrolopyrrolidinone compounds
|
CN104582732A
(en)
|
2012-06-15 |
2015-04-29 |
布里格姆及妇女医院股份有限公司 |
Compositions for treating cancer and methods for making the same
|
WO2014016848A2
(en)
|
2012-07-24 |
2014-01-30 |
Laurus Labs Private Limited |
Solid forms of tyrosine kinase inhibitors, process for the preparation and their pharmaceutical composition thereof
|
US9738643B2
(en)
|
2012-08-06 |
2017-08-22 |
Duke University |
Substituted indazoles for targeting Hsp90
|
WO2014041551A1
(en)
|
2012-09-14 |
2014-03-20 |
Natco Pharma Limited |
Formulation comprising imatinib as oral solution
|
CN103664787B
(en)
|
2012-09-17 |
2015-09-09 |
南京圣和药业股份有限公司 |
Alkynes heteroaromatic ring compounds and application thereof
|
WO2014052619A1
(en)
|
2012-09-27 |
2014-04-03 |
Irm Llc |
Piperidine derivatives and compositions as modulators of gpr119 activity
|
US20150238488A1
(en)
|
2012-09-28 |
2015-08-27 |
Hangzhou Bensheng Pharmaceutical Co., Ltd. |
Drug composition for treating tumors and application thereof
|
CA2886744A1
(en)
*
|
2012-10-04 |
2014-04-10 |
Inhibikase Therapeutics, Inc. |
Imatinib derivatives, their preparation and use to treat cancer and bacterial and viral infections
|
US9950047B2
(en)
|
2012-11-05 |
2018-04-24 |
Dana-Farber Cancer Institute, Inc. |
XBP1, CD138, and CS1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions
|
TW201422625A
(en)
|
2012-11-26 |
2014-06-16 |
Novartis Ag |
Solid form of dihydro-pyrido-oxazine derivative
|
CN103848812B
(en)
*
|
2012-12-04 |
2016-08-03 |
北大方正集团有限公司 |
The method of refined imatinib
|
CN103044394A
(en)
*
|
2012-12-20 |
2013-04-17 |
北京理工大学 |
Phenyl aminopyrimidine derivant and preparation method and application thereof
|
EP2749271A1
(en)
|
2012-12-31 |
2014-07-02 |
Deva Holding Anonim Sirketi |
Optimized manufacturing method and pharmaceutical formulation of imatinib
|
US9403827B2
(en)
|
2013-01-22 |
2016-08-02 |
Novartis Ag |
Substituted purinone compounds
|
US9556180B2
(en)
|
2013-01-22 |
2017-01-31 |
Novartis Ag |
Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the P53/MDM2 interaction
|
WO2014124860A1
(en)
|
2013-02-14 |
2014-08-21 |
Boehringer Ingelheim International Gmbh |
Specific pde4b-inhibitors for the treatment of diabetes mellitus
|
WO2014128612A1
(en)
|
2013-02-20 |
2014-08-28 |
Novartis Ag |
Quinazolin-4-one derivatives
|
CN111139256A
(en)
|
2013-02-20 |
2020-05-12 |
诺华股份有限公司 |
Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptors
|
EP2968340A4
(en)
|
2013-03-15 |
2016-08-10 |
Intellikine Llc |
Combination of kinase inhibitors and uses thereof
|
CA2903577C
(en)
|
2013-03-15 |
2023-10-17 |
Boehringer Ingelheim International Gmbh |
Use of linagliptin in cardio- and renoprotective antidiabetic therapy
|
WO2014155268A2
(en)
|
2013-03-25 |
2014-10-02 |
Novartis Ag |
Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity
|
US9611283B1
(en)
|
2013-04-10 |
2017-04-04 |
Ariad Pharmaceuticals, Inc. |
Methods for inhibiting cell proliferation in ALK-driven cancers
|
EP2803353B1
(en)
|
2013-05-14 |
2018-05-23 |
Hetero Research Foundation |
Compositions of Imatinib
|
US20150018376A1
(en)
|
2013-05-17 |
2015-01-15 |
Novartis Ag |
Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof
|
UY35675A
(en)
|
2013-07-24 |
2015-02-27 |
Novartis Ag |
SUBSTITUTED DERIVATIVES OF QUINAZOLIN-4-ONA
|
WO2015022663A1
(en)
|
2013-08-14 |
2015-02-19 |
Novartis Ag |
Compounds and compositions as inhibitors of mek
|
US9227969B2
(en)
|
2013-08-14 |
2016-01-05 |
Novartis Ag |
Compounds and compositions as inhibitors of MEK
|
WO2015022664A1
(en)
|
2013-08-14 |
2015-02-19 |
Novartis Ag |
Compounds and compositions as inhibitors of mek
|
US9670194B2
(en)
|
2013-09-22 |
2017-06-06 |
Calitor Sciences, Llc |
Substituted aminopyrimidine compounds and methods of use
|
EP3057581B1
(en)
|
2013-10-17 |
2019-09-04 |
Sartar Therapeutics Ltd |
Compositions comprising phosphodiesterase inhibitors for use in the treatment of a solid tumor in a human patient
|
JP6307088B2
(en)
|
2013-10-23 |
2018-04-04 |
中外製薬株式会社 |
Quinazolinone and isoquinolinone derivatives
|
WO2015084804A1
(en)
|
2013-12-03 |
2015-06-11 |
Novartis Ag |
Combination of mdm2 inhibitor and braf inhibitor and their use
|
WO2015148714A1
(en)
|
2014-03-25 |
2015-10-01 |
Duke University |
Heat shock protein 70 (hsp-70) receptor ligands
|
WO2015145388A2
(en)
|
2014-03-27 |
2015-10-01 |
Novartis Ag |
Methods of treating colorectal cancers harboring upstream wnt pathway mutations
|
MX2016012574A
(en)
|
2014-03-28 |
2017-09-26 |
Calitor Sciences Llc |
Substituted heteroaryl compounds and methods of use.
|
AU2015241198A1
(en)
|
2014-04-03 |
2016-11-17 |
Invictus Oncology Pvt. Ltd. |
Supramolecular combinatorial therapeutics
|
US9630944B2
(en)
|
2014-04-04 |
2017-04-25 |
F.I.S.—Fabbrica Italiana Sintetici S.p.A. |
Process for preparing Imatinib and salts thereof, free of genotoxic impurity F
|
WO2015156674A2
(en)
|
2014-04-10 |
2015-10-15 |
Stichting Het Nederlands Kanker Instituut |
Method for treating cancer
|
WO2016011658A1
(en)
|
2014-07-25 |
2016-01-28 |
Novartis Ag |
Combination therapy
|
CA2954862A1
(en)
|
2014-07-31 |
2016-02-04 |
Novartis Ag |
Combination therapy
|
WO2016059220A1
(en)
|
2014-10-16 |
2016-04-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Tcr-activating agents for use in the treatment of t-all
|
CN105585556A
(en)
*
|
2014-11-13 |
2016-05-18 |
连云港杰瑞药业有限公司 |
Synthetic method of imatinib
|
US9938257B2
(en)
|
2015-09-11 |
2018-04-10 |
Calitor Sciences, Llc |
Substituted heteroaryl compounds and methods of use
|
EP3407874B1
(en)
|
2016-01-25 |
2024-05-22 |
KRKA, d.d., Novo mesto |
Fast dispersible pharmaceutical composition comprising tyrosine-kinase inhibitor
|
BR112018069515A2
(en)
|
2016-03-25 |
2019-04-16 |
Ab Science |
use of masitinib to treat a subpopulation of patients with amyotrophic lateral sclerosis
|
WO2017184956A1
(en)
|
2016-04-22 |
2017-10-26 |
Duke University |
Compounds and methods for targeting hsp90
|
JP2019517542A
(en)
|
2016-06-10 |
2019-06-24 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Combination of linagliptin and metformin
|
EP3257499A1
(en)
|
2016-06-17 |
2017-12-20 |
Vipharm S.A. |
Process for preparation of imatinib methanesulfonate capsules
|
CN107652269A
(en)
*
|
2016-07-26 |
2018-02-02 |
江苏豪森药业集团有限公司 |
Methanesulfonic acid fluorine imatinib purification of intermediate method
|
US20190209669A1
(en)
|
2016-08-23 |
2019-07-11 |
Oncopep, Inc. |
Peptide vaccines and durvalumab for treating breast cancer
|
WO2018039203A1
(en)
|
2016-08-23 |
2018-03-01 |
Oncopep, Inc. |
Peptide vaccines and durvalumab for treating multiple myeloma
|
CN107805240A
(en)
*
|
2016-09-08 |
2018-03-16 |
中国科学院合肥物质科学研究院 |
A kind of new PDGFR kinase inhibitors and application thereof
|
ES2912269T3
(en)
|
2016-09-27 |
2022-05-25 |
Cero Therapeutics Inc |
Chimeric engulfment receptor molecules
|
US10207998B2
(en)
|
2016-09-29 |
2019-02-19 |
Duke University |
Substituted benzimidazole and substituted benzothiazole inhibitors of transforming growth factor-β kinase and methods of use thereof
|
US10927083B2
(en)
|
2016-09-29 |
2021-02-23 |
Duke University |
Substituted benzimidazoles as inhibitors of transforming growth factor-β kinase
|
EP3333162A1
(en)
|
2016-12-12 |
2018-06-13 |
Silesian Catalysts sp. z o.o. |
Metod for preparing n-(2-methyl-5-nitrophenyl)-4-(pyridin-3-yl)pyrimidin-2-amine
|
CN107089969B
(en)
*
|
2017-04-26 |
2020-04-24 |
黑龙江鑫创生物科技开发有限公司 |
Method for synthesizing imatinib intermediate
|
US11708423B2
(en)
|
2017-09-26 |
2023-07-25 |
Cero Therapeutics, Inc. |
Chimeric engulfment receptor molecules and methods of use
|
WO2019083960A1
(en)
|
2017-10-24 |
2019-05-02 |
Oncopep, Inc. |
Peptide vaccines and hdac inhibitors for treating multiple myeloma
|
JP2021500409A
(en)
|
2017-10-24 |
2021-01-07 |
オンコペップ, インコーポレイテッド |
Peptide vaccines and pembrolizumab for treating breast cancer
|
US10683297B2
(en)
|
2017-11-19 |
2020-06-16 |
Calitor Sciences, Llc |
Substituted heteroaryl compounds and methods of use
|
EP3730483B1
(en)
|
2017-12-21 |
2023-08-30 |
Hefei Institutes of Physical Science, Chinese Academy of Sciences |
Class of pyrimidine derivative kinase inhibitors
|
AU2019209960B2
(en)
|
2018-01-20 |
2023-11-23 |
Sunshine Lake Pharma Co., Ltd. |
Substituted aminopyrimidine compounds and methods of use
|
CA3093973A1
(en)
|
2018-03-28 |
2019-10-03 |
Cero Therapeutics, Inc. |
Cellular immunotherapy compositions and uses thereof
|
US20210087251A1
(en)
|
2018-03-28 |
2021-03-25 |
Cero Therapeutics, Inc. |
Chimeric tim4 receptors and uses thereof
|
WO2019191339A1
(en)
|
2018-03-28 |
2019-10-03 |
Cero Therapeutics, Inc. |
Expression vectors for chimeric engulfment receptors, genetically modified host cells, and uses thereof
|
WO2020016232A1
(en)
|
2018-07-17 |
2020-01-23 |
Boehringer Ingelheim International Gmbh |
Cardiosafe antidiabetic therapy
|
AU2019306036A1
(en)
|
2018-07-17 |
2020-12-17 |
Boehringer Ingelheim International Gmbh |
Cardio- and renosafe antidiabetic therapy
|
EP3826988A4
(en)
|
2018-07-24 |
2023-03-22 |
Hygia Pharmaceuticals, LLC |
Compounds, derivatives, and analogs for cancer
|
BR112022000571A2
(en)
|
2019-07-15 |
2022-03-15 |
Intas Pharmaceuticals Ltd |
Pharmaceutical composition and process for preparing a pharmaceutical composition comprising imatinib or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients in powder form
|
US20240058446A1
(en)
|
2019-10-03 |
2024-02-22 |
Cero Therapeutics, Inc. |
Chimeric tim4 receptors and uses thereof
|
WO2021097256A1
(en)
|
2019-11-14 |
2021-05-20 |
Cohbar, Inc. |
Cxcr4 antagonist peptides
|
WO2021185844A1
(en)
|
2020-03-16 |
2021-09-23 |
Pvac Medical Technologies Ltd |
Use of substance and pharmaceutical composition thereof, and medical treatments or uses thereof
|
WO2021233534A1
(en)
|
2020-05-20 |
2021-11-25 |
Pvac Medical Technologies Ltd |
Use of substance and pharmaceutical composition thereof, and medical treatments or uses thereof
|
WO2021228983A1
(en)
|
2020-05-13 |
2021-11-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
A pharmaceutical composition comprising an arsenic compound, an inductor of type-1 ifn and a protein kinase inhibitor for treating cancer
|
EP4192509A1
(en)
|
2020-08-05 |
2023-06-14 |
Ellipses Pharma Ltd |
Treatment of cancer using a cyclodextrin-containing polymer-topoisomerase inhibitor conjugate and a parp inhibitor
|
WO2022036287A1
(en)
|
2020-08-14 |
2022-02-17 |
Cero Therapeutics, Inc. |
Anti-cd72 chimeric receptors and uses thereof
|
WO2022036265A1
(en)
|
2020-08-14 |
2022-02-17 |
Cero Therapeutics, Inc. |
Chimeric tim receptors and uses thereof
|
WO2022036285A1
(en)
|
2020-08-14 |
2022-02-17 |
Cero Therapeutics, Inc. |
Compositions and methods for treating cancer with chimeric tim receptors in combination with inhibitors of poly (adp-ribose) polymerase
|
WO2022047259A1
(en)
|
2020-08-28 |
2022-03-03 |
California Institute Of Technology |
Synthetic mammalian signaling circuits for robust cell population control
|
TW202237638A
(en)
|
2020-12-09 |
2022-10-01 |
日商武田藥品工業股份有限公司 |
Compositions of guanylyl cyclase c (gcc) antigen binding agents and methods of use thereof
|
KR20230160242A
(en)
|
2021-02-26 |
2023-11-23 |
켈로니아 테라퓨틱스, 인코포레이티드 |
Lymphocyte-targeted lentiviral vectors
|
WO2023010097A1
(en)
|
2021-07-28 |
2023-02-02 |
Cero Therapeutics, Inc. |
Chimeric tim4 receptors and uses thereof
|
WO2024030441A1
(en)
|
2022-08-02 |
2024-02-08 |
National University Corporation Hokkaido University |
Methods of improving cellular therapy with organelle complexes
|